<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196309</url>
  </required_header>
  <id_info>
    <org_study_id>79/09-02-2018</org_study_id>
    <secondary_id>427/01-06-2018</secondary_id>
    <nct_id>NCT04196309</nct_id>
  </id_info>
  <brief_title>Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization</brief_title>
  <acronym>LOW-RAO</acronym>
  <official_title>A Prospective, Randomized, Open-label Study to Evaluate the Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the LOW-RAO study is to determine the most effective treatment for radial&#xD;
      artery occlusion (RAO) after transradial coronary catheterization (both angiography and PCI).&#xD;
      This is a prospective, single-center, randomized controlled, open-label study that will&#xD;
      randomize patients with RAO into two groups, one receiving anticoagulation with&#xD;
      low-molecular-weight-heparin (LMWH) and the other receiving no anticoagulation. RAO will be&#xD;
      detected by radial artery ultrasound up to 24 hours after the procedure.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
        1. Primary objective:&#xD;
&#xD;
           a. To evaluate the effect of treatment with LMWH, in patients (both symptomatic and&#xD;
           asymptomatic) with RAO after a coronary catheterization procedure (both angiography and&#xD;
           percutaneous coronary intervention-PCI), in improving patency rates of the radial artery&#xD;
           at 1 month after the procedure, compared with no-LMWH treatment.&#xD;
&#xD;
        2. Secondary objectives:&#xD;
&#xD;
             1. To compare RAO as defined by different methods (pulse palpation, modified Allen's&#xD;
                test, reverse Barbeau test, radial artery ultrasound).&#xD;
&#xD;
             2. To compare local access site and systemic complications (bleeding events,&#xD;
                pseudoaneurysm, arteriovenous fistula) at 1 month after the procedure in the LMWH&#xD;
                and no-LMWH groups.&#xD;
&#xD;
             3. To evaluate RAO incidence in coronary angiography and PCI groups.&#xD;
&#xD;
             4. To determine risk factors for RAO in coronary catheterization procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of the radial artery as an access site for coronary catheterization procedures, is&#xD;
      constantly increasing because of lower rate of access site complications, shorter hospital&#xD;
      stay, improved patient comfort and safe hemostasis. Radial artery occlusion remains a concern&#xD;
      after transradial procedures, with a varied incidence, ranging from 5 to 38% as reported in&#xD;
      the literature and probably reflecting different evaluation methods (pulse palpation versus&#xD;
      ultrasound).&#xD;
&#xD;
      Although perceived as usually asymptomatic, registry data report that RAO may be symptomatic&#xD;
      in up to 58.8% of patients, presenting as pain in the forearm, numbness/ paresthesia, paresis&#xD;
      or acute ischemia. Moreover RAO excludes the affected vessel from future catheterization&#xD;
      procedures, hemodialysis shunts, invasive hemodynamic monitoring, coronary arterial bypass&#xD;
      grafting.&#xD;
&#xD;
      Spontaneous recanalization of the vessel after RAO ranges from 5.4 to 47% at 1-month follow&#xD;
      up. Today there is no evidence-based therapy, in the frame of a randomized control study, for&#xD;
      the treatment of RAO. Heparinization has been found to be effective in reducing the&#xD;
      occurrence of radial artery occlusion and short-term treatment with low-molecular-weight&#xD;
      heparin (LMWH) in symptomatic patients increases the patency rate of the radial artery after&#xD;
      coronary catheterization procedures, without increasing bleeding complications, as depicted&#xD;
      by registry data.&#xD;
&#xD;
      This is a prospective, randomized, multicenter study that will enroll, after informed written&#xD;
      consent, all consecutive patients presenting with RAO, after a coronary catheterization&#xD;
      procedure (both angiography and PCI) through the transradial access and having successfully&#xD;
      received at least one radial artery sheath of any size at the end of the procedure.&#xD;
&#xD;
      RAO will be diagnosed by radial artery ultrasound (2D, Doppler, colour) performed in all&#xD;
      patients after sheath removal and successful local hemostasis and before hospital discharge.&#xD;
      Clinical evaluation of radial artery patency with pulse palpation, modified Allen's test and&#xD;
      reverse Barbeau test will be also applied in all patients.&#xD;
&#xD;
      Patients diagnosed with RAO will be randomized 1:1 into two groups:&#xD;
&#xD;
        1. Treatment group, that will receive LMWH (tinzaparin) for 1 month (at&#xD;
           body-weight-adjusted therapeutic dose).&#xD;
&#xD;
        2. Control group, that will not receive additional LMWH. All asymptomatic patients, with&#xD;
           patent radial artery at initial work-up, will be provided with the opportunity to return&#xD;
           to the center for further evaluation, clinically and by ultrasound, if they become&#xD;
           symptomatic at any time after hospital discharge, in order to diagnose late RAO.&#xD;
&#xD;
      They will also be provided with the opportunity to be randomized to LMWH or not in case RAO&#xD;
      is diagnosed and after informed written consent.&#xD;
&#xD;
      Patients already on anticoagulation for any other reason will neither be excluded nor&#xD;
      randomized, but will be followed-up as the randomized ones, in order to collect data from&#xD;
      this patient population.&#xD;
&#xD;
      All patients with RAO will be re-evaluated by radial artery ultrasound at 1-, 2- 4- weeks to&#xD;
      determine radial artery patency and record any bleeding complications according to the EASY&#xD;
      (Early Discharge After Transradial Stenting of Coronary Arteries) Hematoma Classification and&#xD;
      the BARC (Bleeding Academic Research Consortium) bleeding definition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial artery patency</measure>
    <time_frame>1 month</time_frame>
    <description>To evaluate the effect of treatment with LMWH, in patients (both symptomatic and asymptomatic) with RAO after a coronary catheterization procedure (both angiography and percutaneous coronary intervention-PCI), in improving patency rates of the radial artery at 1 month after the procedure, compared with no-LMWH treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>1 month</time_frame>
    <description>To compare bleeding events (based on the BARC bleeding definition) at 1 month after the procedure between the LMWH and no-LMWH groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAO incidence</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate RAO incidence in coronary angiography and PCI groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at the forearm</measure>
    <time_frame>1 month</time_frame>
    <description>To compare incidence of pain at any region of the forearm at 1 month after the procedure between the LMWH and no-LMWH groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arterial Occlusion</condition>
  <arm_group>
    <arm_group_label>Tinzaparin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin</intervention_name>
    <description>LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)</description>
    <arm_group_label>Tinzaparin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (both male and female) undergoing a coronary catheterization procedure (both&#xD;
             angiography and PCI) through the transradial access and having successfully received&#xD;
             at least one radial artery sheath of any size at the end of the procedure.&#xD;
&#xD;
          -  Radial artery occlusion confirmed by ultrasound (2D, Doppler, colour)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Unable to provide informed written consent&#xD;
&#xD;
          -  Any contraindication to receive LMWH.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonios Ziakas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Cardiology Department, University General Hospital AHEPA, Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthaios V. Didagelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Cardiology Department, University General Hospital AHEPA, Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1st Cardiology Department, University General Hospital AHEPA</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Matthaios Didagelos</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>radial artery occlusion</keyword>
  <keyword>coronary catheterization</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

